Moreover, targeting BCL6 high expression with BCL6-peptide inhibitor has an anti-proliferative effect in leukemia cells and the BCL6-peptide inhibitor strongly enhances the effect of PKI imatinib on apoptosis of CML cells [44, 45]. This evidence concerns the gene BCL6 and chronic myelogenous leukemia, BCR-ABL1 positive.